# Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

> **NCT01919554** · PHASE1 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 37 (actual)

## Conditions studied

- Allergic Rhinitis Due to House Dust Mite

## Interventions

- **BIOLOGICAL:** 500 IR house dust mites allergen extract tablet
- **BIOLOGICAL:** 1000 IR house dust mites allergen extract tablet
- **BIOLOGICAL:** 1500 IR house dust mites allergen extract tablet
- **BIOLOGICAL:** Placebo tablet

## Key facts

- **NCT ID:** NCT01919554
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919554, "Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01919554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*